



FRAXA Grant/Fellowship Contract

INTRODUCTION

FRAXA Research Foundation offers a grants and fellowships program designed to encourage research aimed at finding a specific treatment for fragile X syndrome.

- Fellowships are offered to support postdoctoral fellows who want to pursue research in fragile X.
- FRAXA also offers investigator-initiated program grants for innovative studies aimed at developing and characterizing new therapeutic approaches for the treatment and ultimate cure of fragile X syndrome.

FRAXA is particularly interested in preclinical studies of potential pharmaceutical and genetic treatments and studies aimed at understanding the function of the FMR1 gene. New applications are considered once each year; the deadline is February 1, or the following Monday if the 1st falls on a Saturday or Sunday. Renewals are reviewed on a rolling basis; renewals are due 60 days before the start date of the second year of funding.

PURPOSE OF GRANTS/FELLOWSHIPS

The purpose of this grant program is to promote research aimed at finding a specific treatment for fragile X syndrome. FRAXA's goal is to bring practical treatment into current medical practice as quickly as possible; therefore, preference will be given to research projects that have a clear practical application and the results of which will be shared with other qualified researchers in a timely fashion.

ELIGIBILITY FOR GRANTS/FELLOWSHIPS

Institutions receiving grants must be exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, if in the United States. Institutions outside the U.S. must be nonprofit educational institutions. Individuals nominated by applicant institutions for the postdoctoral fellowship should have training and experience at least equal to the Ph.D. or M.D. level. No grants or fellowships are payable to individuals.

ACCEPTABLE COSTS

Acceptable costs covered by FRAXA postdoctoral fellowships are limited to:

- Postdoctoral salary and fringe benefits
- Consumable supplies used for the funded project
- Animal care (if specifically for the funded project)



These limitations do not apply to investigator-initiated program grants. FRAXA reserves the right to cover any item if explicitly authorized by FRAXA's Board of Directors. However, FRAXA is unable to pay for indirect costs under any circumstances.

Fellowships and grants are awarded for one year unless specifically authorized for more than one year. A financial report and progress report are required within 90 days following the end of the project. If a project is not initiated within nine months of the date the award is made, the award must be reauthorized by FRAXA's Board of Directors.

AMENDMENT OF POLICIES

FRAXA Research Foundation reserves the right to modify its policies governing grants at any time. The Grantee agrees to abide by any changes or to terminate the grant at the time when such changes become effective. Failure to abide by the policies governing grants shall be considered sufficient grounds for cancellation of a grant or refusal to consider any pending application by the grantee.

PROHIBITION OF DISCRIMINATION

No person shall be excluded from participation in or denied the benefits of any program or activity or receiving financial assistance from FRAXA because of race, ethnic origin, religion, sex, or sexual orientation.

HUMAN AND ANIMAL SUBJECTS

Human subjects studied in the course of research conducted under a grant are under no circumstances a responsibility of FRAXA. Human subjects in a program supported by FRAXA shall be volunteers in any survey, study or procedure. Research involving human subjects must have Institutional Review Board approval. If animals are used in the proposed study, written certification must be provided to FRAXA indicating that proper treatment, care, and humane conditions have been provided. Research involving animal subjects must have Institutional Animal Care and Use Committee approval.

OBLIGATIONS OF THE GRANTEE

In accepting a grant, the applying institution undertakes that it will:

- Submit within 90 days following the award period to FRAXA a complete final scientific report on the work pursued. On awards of more than one year duration, a yearly scientific report will be expected.
- Supply an accounting of funds received from FRAXA and expenditures made in such detail and in such manner as may meet Internal Revenue Service procedures.
- Recognize the support of FRAXA in any published article resulting from the work pursued with a credit line reading "Supported in part by a grant from FRAXA Research Foundation."



- Recognize the support of FRAXA in any presentation of the work at professional meetings and conferences.

PUBLICATION AND DISSEMINATION OF RESULTS

FRAXA's purpose in providing grants is to accelerate progress towards treatment for fragile X. Therefore, in accepting an award, the Principal Investigator undertakes to publish the results of the work pursued in the primary literature in a timely fashion. Once published, the reagents, methods, materials, and products of the work must be made available immediately to other qualified researchers.

INTELLECTUAL PROPERTY

“Invention” means all discoveries, improvements, inventions, new concepts and ideas arising from the study together with all related data, results and information. Title to any Invention shall reside with the grantee institution. The grantee institution will notify FRAXA promptly after identifying any Invention that the grantee institution believes is patentable, and will supply FRAXA with copies of that Invention. For a patented Invention conceived and reduced to practice that is subsequently licensed under this grant, FRAXA and the grantee institution will negotiate in good faith to enter into a licensing agreement consistent with the grantee institution's policies and procedures solely for the equitable distribution of net income from the invention, taking into consideration the level of funding provided. Grantee institution shall make commercially reasonable efforts to license the invention for commercial development to a third-party. Unless otherwise agreed to by FRAXA, the institution or other title holder shall agree that, if it or its designee or licensee has not taken effective steps to bring the invention to practical or commercial application through licensing or otherwise on terms that are reasonable in the circumstances within three years after issuance of the patent, FRAXA shall receive an automatic grant of a non-exclusive, indefinite, fully paid-up, royalty-free, transferable, irrevocable world-wide license (with the right to sub-licenses) to advance such invention within the field of fragile X research, diagnosis, and treatment.

PUBLICITY ON WORK UNDER GRANT

The Grantee Institution and Principal Investigator will cooperate with FRAXA in announcement through the news media of grants awarded and in materials prepared to publicize work under the grant. FRAXA will publish periodic descriptions and updates on funded projects in its publications and website.



Project Title: _____

Requested Start Date: _____

We accept the conditions specified above. In particular, we note and accept the provision that results of this research must be shared with other qualified researchers in a timely fashion.

_____	_____	_____
signature - Principal Investigator	PI name - please print or type	Date

_____	_____	_____	_____
Signature – Manager	name - please print or type	Title	Date
Office of Grants & Contracts			

Office of Grants & Contracts Address, Contact Name, Phone, and email:

Institution Tax ID:

Award should be made payable to: _____

and mailed to (if different from Office of Grants and Contracts):